Protagonist Therapeutics (PTGX)

• Market cap: $2.34B
• 1 day: -3.20%
• 5 days: -3.46%
• 1 month: -13.68%
• 3 months: -15.63%
• 6 months: 22.77%
• Year to date: 67.81%
• 1 year: 70.72%
• 5 years: 426.10%
• 10 years: 235.90%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Employees: 126

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

179% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 28

34% more capital invested

Capital invested by funds: $2.06B [Q2] → $2.76B (+$704M) [Q3]

27% more funds holding

Funds holding: 187 [Q2] → 237 (+50) [Q3]

17% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 64

2.94% more ownership

Funds ownership: 101.3% [Q2] → 104.24% (+2.94%) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 4 (-4) [Q3]

53% less call options, than puts

Call options by funds: $2.44M | Put options by funds: $5.15M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 27% upside
• Avg. target: $57 44% upside
• High target: $62 58% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target	27% upside $50	Buy Reiterated	10 Dec 2024
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	58% upside $62	Outperform Initiated	6 Dec 2024
Wedbush Yun Zhong 25% 1-year accuracy 1 / 4 met price target	48% upside $58	Outperform Initiated	5 Nov 2024